COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

Global Head & Neck Cancer Drugs Market Expected to Reach $2,281 Million by 2025


quote Increase in incidence of head & neck cancer play a major role in the growth of the head & neck cancer drugs market. Furthermore, increase in use of combination therapy and growth in demand for target immune therapy in the developing countries are expected to boost the market growth in the coming years. quote

Onkar Sumant
Assistant Manager, Healthcare Research at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       

According to a new report published by Allied Market Research, titled,"Head & Neck Cancer Drugs Market by Drug Class and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,"the global head & neck cancer drugs market was valued at $1,295 million in 2017, and is expected to reach $2,281 million by 2025, growing at a CAGR of 7.3% from 2018 to 2025.

Head & neck cancer drugs include chemotherapy and targeted & immune therapeutic drugs, which are used alone or in combination for treatment of throat, larynx, nose, sinuses, lips, salivary glands, and mouth cancers. It is estimated that head & neck cancer drugs market is expected to exhibit significant market growth over the forecast period due to growth in number of target population, rise in demand for combination therapy, advancement in screening & diagnosis procedures, and expected launch of pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, and Bevacizumab.

Based on drug class, the global head & neck cancer drugs market is categorized as chemotherapy agents, immunotherapy, and targeted therapy. Chemotherapy was the major revenue contributing segment in 2017, due to increase in adoption of chemotherapeutics for treatment of head & neck cancer along with radiation therapy and rise in demand for combination therapy. However, the market for immune therapeutic drugs is projected to exhibit the fastest market growth during the forecast period owing to strong presence of pipeline drugs, rise in usage of Yervoy & Keytruda along with the supportive reimbursement policies for usage of immunotherapy drugs in some countries.

According to sales channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online stores. Currently, drug stores & retail pharmacies segment is major revenue contributor due to massive presence of these pharmacies. However, online providers segment is expected to show fastest market growth over the forecast period due to rise in preference for online purchasing of drugs over the traditional methods and increase in awareness about online pharmacy with rise in number of internet users.

Key Findings of the Head & Neck Cancer Drugs Market:

Based on sales channel, the online stores segment is expected to experience fastest market and is projected to grow at a CAGR of 10.2% during the forecast period 2018-2025.
Depending on drug class, the chemotherapy segment held nearly half of the global market share in 2017, and is projected to grow at a CAGR of 4.0% from 2018 to 2025.
Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 9.7% during the forecast period.

North America accounted for nearly one-half of the global market share in 2017, and is expected to remain dominant throughout the forecast period. This was attributed to higher demand for head & neck cancer drugs, higher number target population, favorable reimbursement policies in healthcare system, increase in number of trained medical professionals with wide availability of the advance therapeutics. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to growing prevalence of head & neck cancer, upsurge in demand for head & neck cancer drugs with improvement in healthcare infrastructure.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com


For Media Inquiries, Please Contact

Ram D
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at


First time buyer?
Check offers and discount on this report
To get this report

Click Here

quote Head & Neck Cancer Drugs Market by Drug Class (Chemotherapy, Immunotherapy, and Targeted Therapy) and Sales Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Stores): Global Opportunity Analysis and Industry Forecast, 2018 - 2025 quote

View Report

Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers


Featured Readings


Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

Get Industry Data Alerts

Buy Full Version
"Global Head & Neck Cancer Drugs Market"
Purchase Enquiry